Kiniksa Pharmaceuticals International, plc

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($1.5m) ($64.9m) ($103.2m) ($161.9m) ($161.4m) ($157.9m) $183.4m $14.1m ($43.2m) $59.0m
Depreciation and amortization $2.1m $2.4m $2.4m $2.4m $2.3m $1.7m $1.6m $1.8m
Depreciation $28k $286k $2.1m $2.4m $1.5m $1.2m $1.1m $448k $196k $1.8m
Net amortization (accretion) of discounts on short-term investments ($1.4m) ($3.5m) $123k $664k ($82k) ($1.1m) $441k ($916k)
Amortization Of Securities ($82k) ($1.1m) $441k ($916k) $1.1m
Depreciation Amortization Depletion $2.4m $2.3m $1.7m $1.6m $1.8m
Deferred Income Tax Expense (Benefit) ($197k) ($978k) ($3.2m) $4.4m $11k ($185.5m) ($33.8m) $8.1m $13.0m $14.5m
Deferred Tax ($185.5m) ($33.8m) $8.1m $13.0m $14.5m
Share-based Payment Arrangement, Noncash Expense $897k $5.7m $15.1m $20.9m $25.2m $25.1m $27.1m $30.7m $37.0m $42.1m
Payment, Tax Withholding, Share-based Payment Arrangement $901k $2.2m $5.0m $7.7m
Share-based Payment Arrangement, Expense $897k $5.7m $15.1m $20.9m $25.2m $25.1m $27.1m $30.7m $37.0m $42.1m
Share-based compensation expense $0 $897k $5.7m $15.1m $20.9m $25.2m $25.1m $27.1m $30.7m $37.0m $42.1m
Changes in operating assets and liabilities:
Change In Working Capital ($22.6m) $1.4m $24.8m $24.8m $41.0m
Increase (Decrease) in Accounts Receivable $3.9m $8.7m $8.6m $20.5m ($26.1m) $8.4m
Accounts receivable, net ($3.9m) ($8.7m) ($8.6m) ($20.5m) $26.1m $8.4m
Change In Receivables ($16.3m) ($950k) ($20.5m) $26.1m $8.4m
Changes In Account Receivables ($8.7m) ($8.6m) ($20.5m) $26.1m $8.4m
Increase (Decrease) in Inventories $3.7m $17.9m $9.5m ($4.8m) $28.5m ($22.7m)
Inventory ($3.7m) ($17.9m) ($9.5m) $4.8m ($28.5m) ($22.7m)
Increase (Decrease) in Accounts Payable $277k $1.0m $8.8m ($4.7m) ($5.0m) $1.4m $6.0m $347k ($6.3m) $142k $3.4m
Change In Payables And Accrued Expense $2.3m $17.3m $37.4m $37.6m $3.4m
Accrued expenses, accrued collaboration expenses and other current liabilities $4.1m $9.3m $4.6m $8.8m $10.3m ($3.7m) $16.9m $43.7m $37.5m
Deferred revenue $12.0m $261k $19.6m
Additions to property and equipment included in accrued expenses and other liabilities $1.3m $222k $54k $153k $83k
Change In Accrued Expense ($3.7m) $16.9m $43.7m $37.5m $48.7m
Prepaid expenses and other current assets ($4k) ($1.2m) ($4.8m) ($1.0m) ($1.3m) $2.9m ($3.9m) ($7.1m) ($2.7m) ($22.5m)
Change In Other Current Assets $2.7m $4.6m ($9.7m) ($1.2m) ($2.8m)
Change In Other Current Liabilities ($1.4m) ($3.2m) ($4.0m) $13.2m $21.8m
Net Cash Provided by (Used in) Operating Activities ($882k)
($50.2m) -5591.43%
($81.0m) -61.32%
($158.4m) -95.49%
($136.5m) +13.79%
($126.3m) +7.50%
$5.8m +104.60%
$13.3m +129.05%
$25.7m +93.14%
$138.0m +437.14%
$185.0m +34.05%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $69k $5.3m $3.2m $283k $415k $105k $130k $277k $1.6m ($2.1m)
Gain (Loss) on Disposition of Property Plant Equipment ($66k) ($21k) ($103k) ($33k) ($179k) ($1k) $120k ($128k)
Cash, Cash Equivalents, and Short-term Investments $307.3m $233.4m $323.5m $182.2m $190.6m $206.4m $243.6m $414.1m
Debt Securities, Available-for-sale, Realized Gain (Loss) $0 $0
Purchases of short-term investments ($402.0m) ($488.8m) ($430.2m) ($157.2m) ($135.9m) ($204.9m) ($202.0m) ($386.9m)
Proceeds from the maturities of short-term investments $168.1m $541.2m $407.1m $306.3m $127.8m $175.5m $239.9m $199.5m
Net Cash Provided by (Used in) Investing Activities $168k ($69k) ($239.2m) $49.2m ($23.4m) $128.6m ($8.1m) ($29.6m) $37.7m ($189.0m) ($239.1m)
Cash flows from financing activities:
Payments of Ordinary Dividends, Common Stock $0 $0
Common Stock Issuance $0 $3.4m
Common Stock Payments ($901k) ($2.2m) ($5.0m) ($7.7m) ($11.1m)
Issuance Of Capital Stock $0 $3.4m
Net Common Stock Issuance ($901k) ($2.2m) ($5.0m) ($7.7m) ($11.1m)
Repurchase Of Capital Stock ($901k) ($2.2m) ($5.0m) ($7.7m) ($11.1m)
Net Cash Provided by (Used in) Financing Activities $730k
$39.9m +5363.39%
$346.7m +769.60%
$84.1m -75.74%
$227.1m +170.00%
$5.9m -97.41%
$2.5m -57.25%
$1.5m -40.58%
$12.3m +720.47%
$33.0m +169.22%
$37.7m +14.28%
Net increase (decrease) in cash and cash equivalents ($10.4m) $26.5m ($25.0m) $67.1m $8.2m $245k ($14.8m) $75.6m ($18.0m)
Cash and cash equivalents at beginning of period $45.7m $72.2m $47.1m $114.2m $122.5m $122.7m $108.0m $183.6m $165.6m
Beginning Cash Position $122.5m $122.7m $108.0m $183.6m $192.0m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $45.7m $72.2m $47.1m $114.2m $122.5m $122.7m $108.0m $183.6m $165.6m $175.7m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Proceeds from Stock Options Exercised $377k $1.1m $6.6m $5.3m $2.6m $2.9m
Supplemental disclosure of cash flow information:
Income Taxes Paid, Net $290k $383k $1.7m $482k $1.3m $10.7m $5.6m $2.0m $3.0m
Additional Financial Items
General and Administrative Expense $9.0m $21.6m $35.0m $45.3m
Income Tax Expense (Benefit) $2k ($214k) ($2.0m) $5.2m $1.4m ($172.3m) ($30.7m) $7.0m $29.9m
Investment Income, Interest $529k $4.7m $6.0m $1.1m $97k $9.0m $11.6m
Operating Expenses $65.4m $108.2m $170.0m $157.4m
Non-cash lease expense $1.2m $1.4m $2.6m $3.0m $3.1m $3.1m $3.7m
Contract asset ($7.7m) $7.7m
Other long-term assets ($5.6m) ($3.3m) $2.7m $4.6m ($9.7m) ($1.2m)
Operating lease liabilities ($1.3m) ($1.7m) ($2.6m) ($3.0m) ($3.3m) ($4.0m) ($3.5m)
Other long-term liabilities $326k $478k ($535k) $1.6m $19k ($35k) $16.7m
Proceeds from issuance of Class A ordinary shares under incentive award plans and employee share purchase plan $1.1m $6.6m $5.9m $3.4m $3.7m $17.2m $40.8m
Payments in connection with ordinary stock tendered for employee tax obligations ($901k) ($2.2m) ($5.0m) ($7.7m)
Change in right-of-use asset as a result of new, modified, and terminated leases $1.6m $2.9m $9.6m $1.6m $3.1m
Cash Flow From Continuing Financing Activities $2.5m $1.5m $12.3m $33.0m $37.7m
Cash Flow From Continuing Investing Activities ($8.1m) ($29.6m) $37.7m ($189.0m) ($239.1m)
Change In Account Payable $6.0m $347k ($6.3m) $142k $3.4m
Change In Cash Supplemental As Reported $245k ($14.8m) $75.6m ($18.0m)
Change In Other Working Capital $12.0m $261k $19.6m $19.6m
Change In Payable $6.0m $347k ($6.3m) $142k $3.4m
Change In Prepaid Assets ($3.9m) ($7.1m) ($2.7m) ($22.5m) ($15.8m)
Changes In Cash $245k ($14.8m) $75.6m ($18.0m) ($16.4m)
End Cash Position $122.7m $108.0m $183.6m $165.6m $175.7m
Financing Cash Flow $2.5m
$1.5m -40.58%
$12.3m +720.47%
$33.0m +169.22%
$37.7m +14.28%
Free Cash Flow $5.7m $13.2m $25.4m $136.4m $182.8m
Gain Loss On Sale Of PPE $33k $179k ($24k) ($120k) ($128k)
Investing Cash Flow ($8.1m) ($29.6m) $37.7m ($189.0m) ($239.1m)
Net Intangibles Purchase And Sale ($20.0m) $0 $0
Net Investment Purchase And Sale ($8.1m) ($29.4m) $37.9m ($187.4m) ($236.9m)
Net PPE Purchase And Sale ($14k) ($130k) ($252k) ($1.6m) ($2.1m)
Operating Gains Losses $33k $179k ($24k) ($120k) ($128k)
Other Non Cash Items $3.0m $3.1m $3.1m $3.7m
Proceeds From Stock Option Exercised $3.4m $3.7m $17.2m $40.8m $48.8m
Purchase Of Intangibles ($20.0m) $0 $0
Purchase Of Investment ($135.9m) ($204.9m) ($202.0m) ($386.9m) ($544.2m)
Purchase Of PPE $5.3m $3.2m $283k $415k ($105k) ($130k) ($277k) ($1.6m) ($2.1m)
Sale Of Investment $127.8m $175.5m $239.9m $199.5m $307.2m
Sale Of PPE $91k $0 $25k $0 $0
Stock Based Compensation $25.1m $27.1m $30.7m $37.0m $42.1m